Navigation Links
Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
Date:2/22/2008

al liver function. However, in February 2008, Immtech received reports of additional events related to abnormal kidney function of volunteers from the same safety study. The affected safety study volunteers are receiving full follow-up monitoring and medical care.

The decision to discontinue the development programs was made in conjunction with representatives from the Data Safety Monitoring Board, the Governance Council for the African sleeping sickness grant for the PCP study. The US Food and Drug Administration and Immtech's licensing partners have been consulted.

Dr. Carol Olson, Senior Vice President and Chief Medical Officer of Immtech, stated, "All of the individuals involved in pafuramidine development care deeply about these events. We are grateful to the volunteers and patients who have participated in our clinical trials and are committed to ensuring their safety and well-being. We believe that many subjects have benefited from receiving pafuramidine in Phase 2 and 3 programs. However, given that many patients are located in areas without readily available medical care, we believe the consideration of the potential risk outweighs the potential benefit to further development of pafuramidine. We have gained enormously valuable insight from our work on pafuramidine. This knowledge will greatly benefit Immtech's existing and future new drug discovery and development programs."

Eric L Sorkin, Chairman and Chief Executive Officer of Immtech said, "Since the start of parfuramidine's development we have synthesized many new compounds with improved drug properties. We will continue to focus our efforts on developing the compounds in our library, pursuing licensing agreements and commercial opportunities and further expanding our growth opportunities in China and in other global markets."

About Immtech Pharmaceuticals, Inc.

Immtech is a pharmaceutical company focused on the development and commercialization of new drugs to treat i
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Immtech Announces Posting of Annual Shareholders Meeting Presentation
2. Immtech Reports Fiscal Second Quarter 2008 Results
3. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Chinese SFDA Grants Immtech Fast Track Status
7. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
8. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
9. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
10. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
11. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, modernized ... ingredients (API), provided updates regarding the notice it received ... (the "Exchange") indicating that the Company was below certain ... in Sections 134 and 1101 of the NYSE MKT ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... NEW YORK, March 15, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market ... on the actual market situation, trends and ...
... that closes a hole in patients, hearts is no more ... a new study published in the March 15 issue of ... the CLOSURE I trial, clinical researchers compared a catheter procedure ... or transient ischemic attacks (TIAs) in patients between 18 and ...
Cached Medicine Technology:Vaccines - Asia 2Landmark Study Finds Expensive Catheter Procedure to Close Hole in Heart No More Effective Than Medical Therapy to Prevent Strokes 2Landmark Study Finds Expensive Catheter Procedure to Close Hole in Heart No More Effective Than Medical Therapy to Prevent Strokes 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable source of ... Women's National Soccer Team will face the Australia Women's National Team in conjunction with their ... score of 5-2. Carli Lloyd from the USA team was awarded the Golden Ball ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... die everyday as a direct result of heroin use and eventual overdoses. Thricefold deaths ... is struggling to get a handle on the Sarasota heroin epidemic, which was spurred ...
(Date:7/31/2015)... ... , ... Physical therapy for knee osteoarthritis is an important part of ... the patient from doing what they want or need to do. The patient may have ... stairs. The patient's exercise regime may be limited by the pain in their knee. When ...
(Date:7/31/2015)... Grand Rapids, MI (PRWEB) , ... July 31, ... ... Living Pure Essential Oils are 100% organic, natural, therapeutic-grade oils from ingredients sourced ... founder, Ashley Eilers, explains that “With considerable effort, we have developed the highest-quality ...
(Date:7/31/2015)... ... 31, 2015 , ... “ Crack’em ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... cooking. , Cooking can be a very messy experience, especially when cracking eggs. Cracking ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2Health News:Make Less Mess while Cooking with Crack’em 2
... 20, 2007 -- A Las Vegas business and Oak Ridge ... risk from dehydration or congestive heart failure. , The task ... was to improve and miniaturize Noninvasive Medical Technologies ZOE, a ... fluid. This is of great importance to members of the ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
... Holdings Corp. (Nasdaq:,HMSY) today announced that it will present ... held January 7-10, 2008 at the Westin,St. Francis in ... Robert Holster, Chairman and CEO of HMS Holdings Corp., ... Time., A live broadcast of the Company,s presentation ...
... Funding Supports Phase 3 Program for Lead ... Cogentus Pharmaceuticals,Inc. announced today that it ... million to support the clinical development of ... http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO ), The Series C ...
... Chichester, UK, December 20, 2007 Wiley-Blackwell, the ... John Wiley & Sons, Inc (NYSE: JWa), (NYSE: ... dedicated to improving healthcare decision-making globally, today announced ... with free one-click access to all residents of ...
... LTC,Financial Partners, the nation,s most experienced long ... size since 2005, to more than 400,field underwriters ... what,s,happening in the long term care insurance field, ... *(Photo Caption: LTC Financial CEO Cameron Truesdell.), ...
Cached Medicine News:Health News:Nevada company, ORNL develop potential lifesaver 2Health News:Gloomy forecast for Nobel Direct after 3 years 2Health News:Cogentus Pharmaceuticals Completes $62.5 Million Private Financing 2Health News:Low-income countries now have free, one-click access to Cochrane Library 2Health News:The Long Term Care Insurance Explosion; January Conference to Celebrate Rapid Growth of LTC Protection and Light Fuse of Further Expansion 2
The Leica M500 OH3 is an advanced surgical microscope used by neurosurgeons. It is a smart system combining the best optical performance available on the market with an innovative and unique stand....
Surgical Loupes...
... MAGNETOM Allegra is the ultimate brain ... been optimized for best image quality ... all in a highly compact design. ... diagnosing stroke, epilepsy, tumor and multiple ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: